RxDoctor Payments Data

James Chong, MD

Gastroenterology · Delray Beach, FLNPI 1538130828

Payments from drug & device makers

$14,939in general payments, 2019–2025

Across 761 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$956
  • Bristol Myers Squibb$945
  • QOL Medical, LLC$676
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$14,61198%
  • Education$3282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,939 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$897,920
Medicare patients
1,360
Services billed
26,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$550,710
Humira(Cf) PenAdalimumab13$174,974
Humira PenAdalimumab12$80,925
LinzessLinaclotide89$79,755
Mesalamine64$35,476
ViberziEluxadoline25$33,009
Dexlansoprazole DrDexlansoprazole49$21,408
Pantoprazole Sodium1,200$19,536
Colestipol Hcl178$19,346
SutabSod Sulf/Pot Chloride/Mag Sulf94$14,994
MotegrityPrucalopride Succinate17$13,094
DipentumOlsalazine Sodium12$12,482
Balsalazide Disodium27$8,173
TrulancePlecanatide11$7,256
Sucralfate142$7,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex, Motegrity$1,360$563,80429 claims
AbbVieLinzess, Viberzi$4,402$112,765114 claims
Braintree Laboratories, Inc.Sutab$205$14,99494 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$1,367$10,56034 claims
Ferring Pharmaceuticals Inc.Clenpiq$190$2,87617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →